Astellas Pharma, a Japan-based pharmaceutical company, has announced its decision to shut down one of its subsidiaries, Urogenix, which is a research facility focusing on drug discovery in the field of urology. The company expects to ...
Tags: urology research, resource allocation, clinical potential